Compare Stocks

→ The Next Nvidia? (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTST CannTrust	C$0.64	C$0.64	C$0.38 ▼ C$8.17	C$90.27M	N/A	N/A	N/A
EPIX ESSA Pharma	$6.72 -5.0%	$8.75	$2.56 ▼ $11.67	$297.29M	1.62	138,533 shs	36,276 shs
ETON Eton Pharmaceuticals	$3.06 -2.5%	$4.03	$2.42 ▼ $5.81	$78.61M	1.17	69,310 shs	66,832 shs
SVRA Savara	$4.79 -3.4%	$4.97	$1.76 ▼ $5.70	$661.74M	0.77	851,426 shs	1.20 million shs
ZYNE Zynerba Pharmaceuticals	$1.30 +2.4%	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	862,700 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTST CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
EPIX ESSA Pharma	-4.85%	-9.82%	-22.31%	-17.50%	+148.94%
ETON Eton Pharmaceuticals	-1.57%	-8.45%	-9.77%	-23.04%	-10.03%
SVRA Savara	-3.88%	+4.64%	+5.31%	+16.16%	+166.67%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+213.25%

The Next Nvidia? (Ad)

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTST CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	2.8323 of 5 stars	3.5	4.0	0.0	0.0	2.8	3.3	0.0
ETON Eton Pharmaceuticals	2.3404 of 5 stars	3.5	5.0	0.0	0.0	2.7	0.8	0.0
SVRA Savara	1.6024 of 5 stars	3.5	1.0	0.0	0.0	2.6	1.7	0.6
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTST CannTrust	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	3.00	Buy	$16.50	145.54% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$10.00	226.80% Upside
SVRA Savara	3.00	Buy	$8.20	71.19% Upside
ZYNE Zynerba Pharmaceuticals	2.00	Hold	$1.11	-14.62% Downside

Current Analyst Ratings

Latest EPIX, ETON, CTST, ZYNE, and SVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	SVRA Savara	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
3/4/2024	SVRA Savara	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.00 ➝ $16.00
2/15/2024	SVRA Savara	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTST CannTrust	C$35.22M	2.56	N/A	N/A	N/A	∞
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$3.30 per share	N/A
ETON Eton Pharmaceuticals	$31.64M	2.48	$0.00 per share	998.19	$0.60 per share	5.10
SVRA Savara	N/A	N/A	N/A	N/A	$1.04 per share	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTST CannTrust	-C$10.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	-$26.58M	-$0.59	N/A	N/A	N/A	N/A	-17.41%	-17.04%	5/14/2024 (Estimated)
ETON Eton Pharmaceuticals	-$940K	-$0.03	N/A	∞	N/A	-2.96%	-6.21%	-3.17%	5/9/2024 (Estimated)
SVRA Savara	-$54.70M	-$0.33	N/A	N/A	N/A	N/A	-46.27%	-35.94%	5/20/2024 (Estimated)
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Latest EPIX, ETON, CTST, ZYNE, and SVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/14/2024	Q4 2023	ETON Eton Pharmaceuticals	-$0.04	-$0.09	-$0.05	-$0.09	$7.70 million	$7.31 million
3/7/2024	Q4 2023	SVRA Savara	-$0.11	-$0.09	+$0.02	-$0.09	N/A	N/A
2/13/2024	12/31/2023	EPIX ESSA Pharma	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTST CannTrust	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTST CannTrust	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	40.74	40.74
ETON Eton Pharmaceuticals	N/A	1.65	1.60
SVRA Savara	0.19	15.66	15.66
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Ownership

Institutional Ownership

Company	Institutional Ownership
CTST CannTrust	0.03%
EPIX ESSA Pharma	75.12%
ETON Eton Pharmaceuticals	27.86%
SVRA Savara	87.93%
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
CTST CannTrust	N/A
EPIX ESSA Pharma	14.70%
ETON Eton Pharmaceuticals	13.16%
SVRA Savara	4.58%
ZYNE Zynerba Pharmaceuticals	13.04%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CTST CannTrust	576	141.49 million	N/A	Optionable
EPIX ESSA Pharma	50	44.24 million	37.74 million	Optionable
ETON Eton Pharmaceuticals	30	25.69 million	22.31 million	Optionable
SVRA Savara	N/A	138.15 million	131.82 million	Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

EPIX, ETON, CTST, ZYNE, and SVRA Headlines

Source	Headline
	Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results finance.yahoo.com - October 31 at 7:57 AM
	Why Shares of Harmony Bioscience Are Falling on Friday fool.com - October 13 at 12:59 PM
	New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies markets.businessinsider.com - October 11 at 9:47 AM
	HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE finance.yahoo.com - October 11 at 9:47 AM
	H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 10 at 1:59 PM
	Analysts: ZYNE stock price target of $1.25 in 12 months knoxdaily.com - October 5 at 6:47 PM
	Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions finance.yahoo.com - October 4 at 7:33 PM
	Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 2 at 3:14 PM
	20 Countries With Highest Rate of Epilepsy finance.yahoo.com - September 29 at 6:24 PM
	Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 finance.yahoo.com - September 29 at 1:23 PM
	Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal bizjournals.com - September 27 at 2:42 PM
	Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise knoxdaily.com - September 25 at 8:15 PM
	Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright knoxdaily.com - September 20 at 12:12 PM
	Negative sentiment towards ZYNE reflected in surge in short interest knoxdaily.com - September 15 at 8:27 PM
	Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc finance.yahoo.com - September 14 at 11:23 PM
	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium finance.yahoo.com - September 14 at 6:23 PM
	Zynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statement law.com - September 11 at 4:04 PM
	Positive sentiment towards ZYNE reflected in decline in short interest knoxdaily.com - September 8 at 5:19 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLR bakersfield.com - August 31 at 5:00 PM
	HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE) msn.com - August 16 at 4:20 AM
	Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout biospace.com - August 15 at 6:19 PM
	Zynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much? dhakatribune.com - August 15 at 6:19 PM
	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans? finance.yahoo.com - August 15 at 6:19 PM
	Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNE marketwatch.com - August 14 at 9:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CannTrust

NYSE:CTST

CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

ESSA Pharma

NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Eton Pharmaceuticals

NASDAQ:ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Savara

NASDAQ:SVRA

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Zynerba Pharmaceuticals

NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial